Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 6 January 2026 - 17 January 2026

Johnson & Johnson stock slips — what traders watch before JNJ earnings

Johnson & Johnson stock slips — what traders watch before JNJ earnings

Johnson & Johnson shares closed down 0.41% at $218.66 Friday and were flat after hours. The company reports fourth-quarter earnings January 21, with investors watching for updates on drug approvals and MedTech growth. FDA fast-track reviews and consumer-health deals remain in focus. Kenvue, spun off from J&J, faces a key shareholder vote January 29 on its sale to Kimberly-Clark.
17 January 2026
··
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares rose 2.3% to $218.55 in after-hours trading Wednesday after reporting its Tecvayli drug cut the risk of disease progression or death by 71% in a late-stage multiple myeloma trial. An independent committee recommended unblinding the study. Full results will be presented at an upcoming medical meeting. Investors await the company’s quarterly results next week.
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson shares rose 1.9% to $213.65 Tuesday and held steady after hours as Delaware’s top court ordered a recalculation of a $1 billion damages award tied to the Auris Health acquisition. The ruling could reduce the payout by several hundred million dollars. Investors are watching for J&J’s fourth-quarter results on Jan. 21 and updates from healthcare conferences this week.
14 January 2026
··
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares rose 1.6% to $212.98 Tuesday, outperforming a dip in healthcare stocks. Delaware’s Supreme Court ordered a recalculation of part of a $1 billion damages award tied to the Auris acquisition, which could reduce the payout by hundreds of millions. Legal developments and upcoming drug trial data are in focus ahead of the company’s Jan. 21 earnings call.
13 January 2026
···
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson shares fell 0.7% to $204.39 after announcing a deal with the Trump administration to cut U.S. drug prices in exchange for tariff exemptions. The company will offer some medicines at discounted rates via TrumpRx.gov but did not specify drugs or discount sizes. J&J also unveiled plans for two new U.S. manufacturing plants. Early trial data for its cancer drug amivantamab showed a 70% response rate in a first-line subgroup.
11 January 2026
··
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson shares fell 0.7% to $204.39 Friday after the company agreed to lower U.S. drug prices in exchange for tariff exemptions, with terms undisclosed. J&J will join the TrumpRx.gov platform and said it plans two new U.S. manufacturing sites. The S&P 500 rose 0.65%. Investors await the JPMorgan healthcare conference and J&J’s Jan. 21 earnings call.
10 January 2026
··
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
10 January 2026
····
Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

New York, January 6, 2026, 21:28 EST — Market closed Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology. The developments matter now because investors are looking for durable growth drivers heading into quarterly results later this month, when management is expected to frame demand trends and the pipeline into 2026. Late-stage filings and mid-stage readouts can move the outlook for a drugmaker even when the stock barely budges on the day, especially for a large-cap name where incremental product wins tend to show up in guidance
7 January 2026
··
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

New York, January 6, 2026, 12:58 EST — Regular session Johnson & Johnson (JNJ.N) shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was up $1.10, or 0.5%, at $205.41 in midday New York trading. The update puts fresh focus on J&J’s drug pipeline at a time investors are leaning on healthcare for steadier earnings and dividends. New medicines are also a key lever for the company as it looks to offset slower growth in mature brands and keep pricing power in its core
6 January 2026
···
1 2 3 4 5 … 7

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop